Postchemotherapy Retroperitoneal Lymph Node Dissection is Effective Therapy in Selected Patients With Elevated Tumor Markers After Primary Chemotherapy Alone
| العنوان: | Postchemotherapy Retroperitoneal Lymph Node Dissection is Effective Therapy in Selected Patients With Elevated Tumor Markers After Primary Chemotherapy Alone |
|---|---|
| المؤلفون: | Richard Bihrle, Lawrence H. Einhorn, Christopher L. Coogan, Richard S. Foster, Ernest R. Smith, Randall G. Rowland, Bruce J. Roth, John P. Donohue |
| المصدر: | Journal of Urology. 160:948-949 |
| بيانات النشر: | Ovid Technologies (Wolters Kluwer Health), 1998. |
| سنة النشر: | 1998 |
| مصطلحات موضوعية: | Adult, Male, medicine.medical_specialty, Adolescent, Urology, medicine.medical_treatment, Retroperitoneal Lymph Node, Retroperitoneal lymph node dissection, Testicular Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Biomarkers, Tumor, Humans, Medicine, Primary chemotherapy, Retroperitoneal Space, Stage (cooking), Neoplasm Staging, Salvage Therapy, Chemotherapy, business.industry, Induction chemotherapy, Cancer, Combination chemotherapy, Middle Aged, medicine.disease, Prognosis, Combined Modality Therapy, Surgery, Lymphatic Metastasis, Lymph Node Excision, Teratoma, business, Follow-Up Studies |
| الوصف: | Objectives Elevated tumor markers after primary chemotherapy for metastatic testis cancer are usually an indication of persistent cancer. Subsequent treatment has usually been salvage chemotherapy. This article examines the possibility that selected patients can achieve long-term disease-free survival with surgery alone. Methods Using a computerized data base of 627 postinduction chemotherapy retroperitoneal lymph node dissections (PC-RPLND), 23 patients with elevated tumor markers who have undergone PC-RPLND after induction chemotherapy alone were identified. Of the 23 patients, 15 were considered candidates for salvage chemotherapy, but instead underwent salvage surgery. Case histories were reviewed to establish selection criteria for PC-RPLND. Results Eight patients originally presented as clinical Stage C, 6 as clinical Stage B-3, and 1 as clinical Stage B-2. All patients initially received cisplatin combination chemotherapy. Twelve patients had an elevated alpha-fetoprotein level and 3 patients had an elevated beta human chorionic gonadotropin level prior to PC-RPLND. Seven patients had rising markers at the time of PC-RPLND. Seven patients had teratoma only in their resected specimen and all have no evidence of disease [NED) at a median of 35 months. Two patients had necrosis only in their RPLND specimen and both are NED at 10 and 42 months. Six patients had cancer in their resected specimen and 2 are NED, 1 is alive with disease, and 3 are dead of disease. Five of the 6 patients with cancer in their resected specimen were the only patients who received postoperative chemotherapy. Conclusions Some patients with modest elevations of tumor markers after induction chemotherapy may only have teratoma or necrosis in the postchemotherapy resected specimen. These patients (n = 9) remain continuously NED. Patients who undergo salvage surgery and have cancer in the resected specimen do less well, but selected patients can be cured with this modality and thus avoid the morbidity of salvage chemotherapy. |
| تدمد: | 1527-3792 0022-5347 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1842631b0f67ba19ba4a71205f48451aTest https://doi.org/10.1016/s0022-5347Test(01)62842-8 |
| حقوق: | CLOSED |
| رقم الانضمام: | edsair.doi.dedup.....1842631b0f67ba19ba4a71205f48451a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15273792 00225347 |
|---|